Event Details

Featuring Robert Anderson, MD, PhD (Novoviah Pharmaceuticals, Brisbane, Australia) and Professor Christopher Jewell, PhD (University of Maryland) discussing the unmet needs and current status of treatments for celiac disease and other autoimmunity indications, along with the potential for tolerogenic immunotherapies in the current treatment landscape. The event also highlighted Vaccitech’s SNAPvax™ platform and other nanoparticle technologies for enabling immunotherapies to induce tolerance, with a review of the latest supporting data.